Chen Zhiqiang

Chen Zhiqiang


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
SXSongtao Xiang
Songtao Xiang
QZQiouHong Zhang
QiouHong Zhang
JWJingJing Wu
JingJing Wu
QTQing Tang
Qing Tang
SHSwei sunny Hann
Swei sunny Hann
Prostate cancer is one of the most common malignancies in men. The mucin 1 (MUC1) heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features, resulting in a poor outcome. However, the functional role for MUC1 C-terminal domain (MUC1-C) in androgen-independent prostate cancer occurrence and development has remained unclear. Cell viability was measured by MTT assays. Western blot analysis was performed to measure the phosphorylation and protein expression of SAPK/JNK and ERK1/2, and MUC1-C, NF-κB subunit p65 and p50. Exogenous expression of MUC1-C, NF-κB subunit p65 was carried out by transient and electroporated transfection assays. We showed that curcumin inhibited the growth of androgen-independent prostate cancer cells and a synergy was observed in the presence of curcumin and bicalutamide, the androgen receptor antagonist. To further explore the potential mechanism underlining this, we found that curcumin increased the phosphorylation of ERK1/2 and SAPK/JNK, which was enhanced by bicalutamide. In addition, curcumin reduced the protein expression of MUC1-C and NF-κB subunit p65, which were abrogated in the presence of the inhibitors of MEK/ERK1/2 (PD98059) and SAPK/JNK (SP60015). A further reduction was observed in the combination of curcumin with bicalutamide. Moreover, while exogenous expression of MUC1-C had little effect on curcumin-reduced p65, the overexpression of p65 reversed the effect of curcumin on MUC1-C protein expression suggesting that p65 is upstream of MUC1-C. Intriguingly, we showed that exogenous expression of MUC1-C feedback diminished the effect of curcumin on phosphorylation of ERK1/2 and SAPK/JNK, and antagonized the effect of curcumin on cell growth. Our results show that curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein. More importantly, there are synergistic effects of curcumin and bicalutamide. The negative feedback regulatory loop of MUC1-C to ERK1/2 and SAPK/JNK further demonstrates the role of MUC1-C that contributes to the overall responses of curcumin. This study unveils the potential molecular mechanism by which combination of curcumin with bicalutamide enhances the growth inhibition of androgen-independent prostate cancer cells.

21 August 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ZJZhi Jiang
Zhi Jiang
QZQiuping Zou
Qiuping Zou
QCQicheng Chen
Qicheng Chen
JZJunhong Zhang
Junhong Zhang
HTHailin Tang
Hailin Tang
LCLixing Cao
Lixing Cao
Introduction: Previous studies indicated that Wuda Granule (WDG) has been applied in the treatment of gastrointestinal motility disorder (GMD), but the effect and underlying mechanisms is yet to be elucidated. This study aimed to explore the mechanism and pharmacological effect of WDG for GMD via network analysis, verification of animal experiments and clinical experiments.Methods: The chemical components of WDG were identified from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP, http://lsp.nwu.edu.cn/index.php), and the Encyclopedia of Traditional Chinese Medicine (ETCM, http://www.tcmip.cn/ETCM/index.php/Home/Index/) according to oral bioavailability (OB) ≥ 20% and drug-likeness (DL) ≥ 0.10. The targets of WDG compounds were retrieved from the Swiss Target Prediction database (http://www.swisstargetprediction.ch/) and targets related to GMD were retrieved from GeneCards database (https://www.genecards.org/). Network analysis were performed to screen the key active compounds of WDG and its hub targets. Then the pharmacological effect of WDG were verified via vivo experiments in rats and clinical experiments.Results: The results showed that 117 effective active compounds of WDG were screened and 494 targets of WDG compounds targeting GMD were selected. These targets were involved in the biological process of inflammatory regulation and the regulation of gastrointestinal motility. The mechanism was mainly involved in the regulation of PI3K-Akt signaling pathway and Rap1 signaling pathway. In addition, molecular docking analysis suggested that eight key active compounds of WDG may be mainly responsible for the effect of WDG on GMD by targeting HARS, AKT, and PIK3CA, respectively. Animal experiments and clinical trials both suggested that WDG could exert therapeutical effect on GMD via inhibiting inflammation and promoting gastrointestinal motility, it could also improve digestive function of patients with laparoscopic colorectal cancer after surgery.Conclusion: This study was the first to demonstrate that WDG improved GMD mainly via inhibiting inflammatory level and promoting gastrointestinal motility, providing new insights for the understanding of WDG for GMD, inspiration for future research and reference for clinical strategy in terms of the treatment of GMD.

1 March 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
ZJZhi Jiang
Zhi Jiang
QCQicheng Chen
Qicheng Chen
JZJunhong Zhang
Junhong Zhang
LCLixing Cao
Lixing Cao
CZChen Zhiqiang
Chen Zhiqiang

9 May 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DDDechang Diao
Dechang Diao
LWLei Wang
Lei Wang
JWJin Wan
Jin Wan
CZChen Zhiqiang
Chen Zhiqiang
JPJunsheng Peng
Junsheng Peng
LZLiaonan Zou
Liaonan Zou
Mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) has been confirmed to play a pivotal role in tumor carcinogenesis and progression. However, few studies have investigated the role of MEK5 in colorectal cancer (CRC). MEK5 expression was determined by immunohistochemistry (IHC) in tissue microarrays (TMAs) containing 2 groups of tissues, and western blotting was used to confirm MEK5 expression in 8 cases of primary CRC tissues and paired normal mucosa. RNA interference was used to verify the biological function of MEK5 gene in the development of CRC. IHC revealed the expression of MEK5 was higher in tumor tissues (38.1 %), compared with adjacent normal tissue (8.3 %). Western blot showed that, MEK5 expression was upregulated in CRC tumor tissues compared with normal tissue. Analysis of clinical pathology parameters indicated MEK5 overexpression was significantly correlated with the depth of invasion, lymph node metastasis, distant metastasis and histological grade. Survival analysis revealed that MEK5 overexpression negatively correlated with cancer-free survival (hazard ratio 1.64, P = 0.017). RNA interference-mediated knockdown of MEK5 in SW480 colon cancer cells decreased their proliferation, division, migration and invasiveness in vitro and slowed down tumors growth in mice engrafted with the cells. MEK5 plays an important role in CRC progression and may be a potential molecular target for the treatment of CRC.

27 February 2018 in Trials
Verified
Journal Article
Open access
PDF file
HGHuachan Gan
Huachan Gan
JLJinxuan Lin
Jinxuan Lin
ZJZhi Jiang
Zhi Jiang
QCQicheng Chen
Qicheng Chen
LCLixing Cao
Lixing Cao
CZChen Zhiqiang
Chen Zhiqiang
Most patients who undergo abdominal surgery recover bowel movements within a week; however, some suffer prolonged intestinal paralysis or postoperative ileus (POI) leading to complications, such as infection and intestinal adhesions, which can extend hospitalization and increase readmission rates, and consequently increasing healthcare costs. Chinese medicine is effective for accelerating the recovery of gastrointestinal function after abdominal surgery. Xiangbin prescription (XBP) is the standard prescription for this purpose in our hospital; however, randomized controlled trials of it have not yet been conducted. This double-blind, randomized controlled clinical trial aims to recruit patients who have undergone abdominal surgery and experienced postoperative dysmotility to evaluate the efficacy and safety of XBP for preventing POI and accelerating recovery. The research will tackle the common problem of slow recovery of gastrointestinal function after surgery. The participants will be patients who undergo laparoscopic radical resection of rectal carcinoma or laparoscopic panhysterectomy of a benign lesion. Primary outcome measures will be time to first flatus, defecation, normal bowel sounds, and liquid/semi-liquid/general diet. Good Clinical Practice (GCP) standards of efficacy and safety will also be evaluated, along with objective investigation of the mechanism of action of ghrelin. This pivotal trial will be a standardized, scientific, clinical trial designed to evaluate the use of XBP for the recovery of gastrointestinal function after surgery, and it will conform to international standards for clinical trials for the recognition of traditional Chinese medicine. Chinese Clinical Trial Registry, ID: ChiCTR-TRC-14004156 . Registered on 3 January 2014.

28 October 2025 in International Journal of Surgery
Verified
Journal Article
Open access
ZJZhi Jiang
Zhi Jiang
XLXing Li
Xing Li
ZSZhuo Shao
Zhuo Shao
HTHailin Tang
Hailin Tang
JWJianwei Wu
Jianwei Wu
ZMZu-Bing Mei
Zu-Bing Mei
Background: Enhanced recovery after surgery (ERAS) protocols have transformed perioperative care in laparoscopic colorectal surgery, aiming to optimize patient outcomes. However, heterogeneity in reported outcomes across randomized controlled trials (RCTs) limits evidence synthesis and clinical application. A core outcome set (COS) is urgently needed to standardize outcome reporting and enhance research comparability. This study aims to systematically map outcomes reported in ERAS RCTs for laparoscopic colorectal surgery, providing a foundation for developing a tailored COS specific to this subfield. Methods: Following PRISMA guidelines, we searched PubMed, Embase, and the Cochrane Library for RCTs published from inception to April 2025, assessing ERAS protocols in laparoscopic colorectal surgery. Studies were included if they were RCTs comparing ERAS interventions with standard care or other ERAS variants. Data on study characteristics, interventions, and reported outcomes were extracted and categorized into domains using narrative synthesis. Outcome frequency and measurement variability were analyzed. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Results: From 57 included RCTs ( n = 7502 patients), 86 unique outcomes were identified across 9 domains: gastrointestinal recovery (25.6%, e.g., time to first flatus, 45.6% of studies), postoperative pain (18.6%, e.g., Visual Analogue Scale pain scores, 31.6%), hospital stay (14.0%, e.g., length of stay, 38.6%), postoperative complications (15.1%), physical function (9.3%), immune and inflammatory response (7.0%), patient-reported outcomes (4.7%), postoperative nausea and vomiting (3.5%), and economic outcomes (2.3%). Outcome definitions and measurement tools varied widely, with no consistent standardization. Conclusions: This study highlights heterogeneity in ERAS outcome reporting, emphasizing the need for a COS. The identified domains and outcomes provide a foundation for standardizing research, improving evidence quality, and guiding clinical practice.